A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
12 Apr 2019 Status changed from recruiting to discontinued.
12 Apr 2019 According to a TRACON Pharmaceuticals media release, based on a review of TAPPAS trial data, the Independent Data Monitoring Committee (IDMC) recommended to terminate TAPPAS trial. The company also decided to terminate further enrollment in company sponsored trials of TRC105 in oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com